| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mingqing Xu, Sheng Li, Qinghe Xing, Rui Gao, Guoyin Feng, Zhiguang Lin, David St Clair, Lin H. Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. European journal of human genetics : EJHG. vol 18. issue 6. 2010-09-08. PMID:20087404. |
genetic variants in the bdnf gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. |
2010-09-08 |
2023-08-12 |
Not clear |
| Lucia Sara Volonteri, Giancarlo Cerveri, Ilaria Francesca De Gaspari, Maria Luisa Baldi, Maria Laura Rolandi, Pietro Papa, Massimo Carlo Mauri, Claudio Mencacc. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. Psychopharmacology. vol 210. issue 4. 2010-09-07. PMID:20422405. |
it is still common to encounter a partial or no response to antipsychotic treatment in clinical practice, but only individual case reports are currently available concerning the efficacy of long-acting risperidone (rlai) in treatment-resistant schizophrenia. |
2010-09-07 |
2023-08-12 |
Not clear |
| Kohei Yamaguchi, Etsuro Tsutsum. The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. Internal medicine (Tokyo, Japan). vol 49. issue 10. 2010-08-20. PMID:20467177. |
the insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. |
2010-08-20 |
2023-08-12 |
Not clear |
| Kohei Yamaguchi, Etsuro Tsutsum. The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. Internal medicine (Tokyo, Japan). vol 49. issue 10. 2010-08-20. PMID:20467177. |
throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism. |
2010-08-20 |
2023-08-12 |
Not clear |
| Li Yang, Ming Li, Li-bo Tao, Mingliang Zhang, M Deborah Nicholl, Peng Don. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 12 Suppl 3. 2010-08-10. PMID:20586985. |
cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in china. |
2010-08-10 |
2023-08-12 |
Not clear |
| Leslie Citrome, Ari Jaffe, Jerome Levin. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Schizophrenia research. vol 119. issue 1-3. 2010-07-30. PMID:20347267. |
treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. |
2010-07-30 |
2023-08-12 |
Not clear |
| Hiroyuki Uchida, Tarek K Rajji, Benoit H Mulsant, Shitij Kapur, Bruce G Pollock, Ariel Graff-Guerrero, Mahesh Menon, David C Mam. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. Journal of clinical psychopharmacology. vol 29. issue 6. 2010-07-20. PMID:19910723. |
d2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. |
2010-07-20 |
2023-08-12 |
human |
| Hiroyuki Uchida, Tarek K Rajji, Benoit H Mulsant, Shitij Kapur, Bruce G Pollock, Ariel Graff-Guerrero, Mahesh Menon, David C Mam. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. Journal of clinical psychopharmacology. vol 29. issue 6. 2010-07-20. PMID:19910723. |
the objective of this study was to examine the relationship between dopamine d2 receptor blockade by risperidone and the cognitive function in late-life schizophrenia. |
2010-07-20 |
2023-08-12 |
human |
| Hiroyuki Uchida, Tarek K Rajji, Benoit H Mulsant, Shitij Kapur, Bruce G Pollock, Ariel Graff-Guerrero, Mahesh Menon, David C Mam. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. Journal of clinical psychopharmacology. vol 29. issue 6. 2010-07-20. PMID:19910723. |
subjects with schizophrenia or schizoaffective disorder aged 50 or older who were receiving risperidone completed a [c]raclopride positron emission tomography scan to measure d2-binding potential in the striatum. |
2010-07-20 |
2023-08-12 |
human |
| Chuan-Yue Wang, Yu-Tao Xiang, Zhuo-Ji Cai, Yong-Zhen Weng, Qi-Jing Bo, Jing-Ping Zhao, Tie-Qiao Liu, Gao-Hua Wang, Shi-Min Weng, Hong-Yan Zhang, Da-Fang Chen, Wai-Kwong Tang, Gabor S Ungvar. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. The American journal of psychiatry. vol 167. issue 6. 2010-07-20. PMID:20231321. |
risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. |
2010-07-20 |
2023-08-12 |
Not clear |
| Arun K Tiwari, Clement C Zai, Olga Likhodi, Annika Lisker, Deepika Singh, Renan P Souza, Poonam Batra, Syed H E Zaidi, Sheng Chen, Fang Liu, Imke Puls, Herbert Y Meltzer, Jeffrey A Lieberman, James L Kennedy, Daniel J Mülle. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 6. 2010-07-12. PMID:20107430. |
twenty tag snps were analyzed in 183 patients who underwent treatment (with either clozapine, olanzapine, haloperidol, or risperidone) for chronic schizophrenia were evaluated for antipsychotic-induced weight gain for up to 14 weeks. |
2010-07-12 |
2023-08-12 |
Not clear |
| Carla M Canuso, Augusto Grinspan, Amir Kalali, Chandrasekharrao Venkata Damaraju, Ursula Merriman, Larry Alphs, Awad George Awa. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. International clinical psychopharmacology. vol 25. issue 3. 2010-07-01. PMID:20216424. |
medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. |
2010-07-01 |
2023-08-12 |
human |
| Carla M Canuso, Augusto Grinspan, Amir Kalali, Chandrasekharrao Venkata Damaraju, Ursula Merriman, Larry Alphs, Awad George Awa. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. International clinical psychopharmacology. vol 25. issue 3. 2010-07-01. PMID:20216424. |
participants with schizophrenia who were suboptimally responsive to risperidone reported improved medication satisfaction after initiation of paliperidone er. |
2010-07-01 |
2023-08-12 |
human |
| Eduard Parellada, Filippos Kouniakis, Aldona Siurkute, Andreas Schreiner, Liana Do. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. International clinical psychopharmacology. vol 25. issue 3. 2010-07-01. PMID:20305567. |
safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. |
2010-07-01 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Manabu Saito, Taku Nakagami, Norio Sugawara, Yasushi Sato, Shoko Tsuchimine, Hanako Furukori, Sunao Kanek. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 3. 2010-06-24. PMID:20170699. |
gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. |
2010-06-24 |
2023-08-12 |
human |
| David C Henderson, Bikash Sharma, Xiaoduo Fan, Paul M Copeland, Christina P Borba, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 22. issue 1. 2010-06-24. PMID:20196981. |
dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. |
2010-06-24 |
2023-08-12 |
Not clear |
| David C Henderson, Bikash Sharma, Xiaoduo Fan, Paul M Copeland, Christina P Borba, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 22. issue 1. 2010-06-24. PMID:20196981. |
the goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia. |
2010-06-24 |
2023-08-12 |
Not clear |
| Emmanouil N Rizos, Athanasia Papadopoulou, Efstathios Laskos, Panagiota G Michalopoulou, Anastasia Kastania, Dimitrios Vasilopoulos, Konstantinos Katsafouros, Lefteris Lykoura. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 11. issue 2 Pt 2. 2010-06-14. PMID:20218789. |
we measured serum bdnf levels in 47 patients with schizophrenia during a relapse and again 6 weeks after administration of antipsychotic treatment (14 on risperidone, 18 on haloperidol, 10 on olanzapine and five on amisulpride) and in 44 healthy volunteers. |
2010-06-14 |
2023-08-12 |
human |
| Anna Dietrich-Muszalska, Jolanta Rabe-Jablonska, Pawel Nowak, Bogdan Konte. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 11. issue 2 Pt 2. 2010-06-14. PMID:20218792. |
the effects of antipsychotic drugs on blood platelet function are not fully explained, therefore the purpose of the present study was to examine and compare the effects of the second-generation antipsychotic drugs used in schizophrenia (clozapine, risperidone and olanzapine), with the effects of the first generation antipsychotic, haloperidol, on the platelet aggregation induced by adp in vitro. |
2010-06-14 |
2023-08-12 |
Not clear |
| M Schmauss, B Diekamp, M Gerwe, A Schreiner, B Ibac. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? Pharmacopsychiatry. vol 43. issue 2. 2010-06-11. PMID:20131207. |
does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? |
2010-06-11 |
2023-08-12 |
Not clear |